LINC01116 as A Potential Drug Target Or Biomarker for Alzheimer's Disease

Target Name: LINC01116

NCBI ID: G375295

LINC01116

Other Name(s): TALNEC2 | Tumor associated lncRNA expressed in chromosome 2 | Long intergenic non-protein coding RNA 1116 | long intergenic non-protein coding RNA 1116

LINC01116 as A Potential Drug Target Or Biomarker for Alzheimer's Disease

LINC01116 (TALNEC2) is a protein that is expressed in various tissues of the body, including the brain. It is a member of the TAL1/2 family of transcription factors, which are known for their role in regulating gene expression. LINC01116 has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease.

Recent studies have suggested that LINC01116 may be a drug target (or biomarker) for the treatment of Alzheimer's disease. One reason for this suggestion is that LINC01116 has been shown to be overexpressed in the brains of individuals with Alzheimer's disease. Overexpression of LINC01116 has been associated with the development of neurodegeneration, which is a hallmark of Alzheimer's disease.

Another reason for LINC01116 being considered a drug target is its role in the regulation of cellular processes that are involved in the development and progression of Alzheimer's disease. For example, LINC01116 has been shown to be involved in the regulation of neurotransmitter release, which is important for the function of neurons in the brain. Additionally, LINC01116 has been shown to be involved in the regulation of cellular signaling pathways that are involved in the development and progression of Alzheimer's disease.

In addition to its potential role as a drug target, LINC01116 has also been shown to be a potential biomarker for the diagnosis and progression of Alzheimer's disease. The overexpression of LINC01116 has been shown to be associated with the development of neurodegeneration in individuals with Alzheimer's disease, which could make LINC01116 a useful biomarker for the disease. Additionally, LINC01116 has been shown to be expressed in the brains of individuals with Alzheimer's disease, which could make it a useful target for diagnostic studies of the disease.

Overall, LINC01116 is a protein that has the potential to be a drug target (or biomarker) for the treatment of Alzheimer's disease. Further research is needed to fully understand its role in the development and progression of the disease.

Protein Name: Long Intergenic Non-protein Coding RNA 1116

The "LINC01116 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01116 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets